Change over period: —
NSE · BETA
Beta Drugs Ltd
-32.5% from the 52-week high · +74.9% above the low
Beta Drugs Ltd. engages in the manufacturing and trading of pharmaceuticals. The company is headquartered in Panchkula, Haryana. The company went IPO on 2017-10-12. The firm offers a range of oncology products including tablets, capsules and injections. The firm offers a portfolio consisting of approximately 50 products catering to various oncology diseases, including breast, brain, bone, lung, mouth, head and neck, prostate, leukemia, lymphoma and supportive cancer and others. The Company’s oncology portfolio includes various brands, such as AB-PACLI, ADBIRON, ADCARB, ADCIST, Adlante, ADLEAP, ADMIDE, ADOXI, CAPAD, ADTHAL, Triodelta and others.
The short version. Return on equity was 17.0% in Mar 2026. Promoter holding was 58.91% in Sep 2026, down 7.82 points over 8 quarters.
1 · The price
How has the stock traded?
Beta Drugs Ltd trades 32.5% below its 52-week high and 74.9% above its 52-week low.
2 · The business
Is it growing?
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | 137 | 126 | 94 | 87 |
| Net profit | 20 | 17 | 9 | 9 |
| Net margin % | 14.6 | 13.7 | 9.6 | 9.8 |
| EPS (₹) | 18.0 | 15.49 | 8.93 | 8.44 |
Annual
| FY2026 | FY2025 | |
|---|---|---|
| Revenue | 385 | 362 |
| Net profit | 41 | 42 |
| Net margin % | 10.8 | 11.7 |
| EPS (₹) | 40.92 | 42.02 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 17.0% in Mar 2026; debt to equity is 0.60.
Profitability · 2 years
Returns and margins
| Mar 2026 | Mar 2025 | |
|---|---|---|
| Return on equity % | 17.0 | 21.5 |
| Return on capital % | 18.0 | 19.2 |
| EBITDA margin % | 21.9 | 20.7 |
| Net margin % | 10.5 | 11.5 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Down 7.82 pts over 8 quarters.
Up 0.22 pts over 8 quarters.
Up 6.28 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 66.73 | 66.73 | 66.73 | 66.73 | 64.9 | 64.63 | 59.1 | 58.91 | -7.82 |
| FII | 1.15 | 0.9 | 0.9 | 0.9 | 1.14 | 1.16 | 1.02 | 1.37 | +0.22 |
| DII | 0.17 | 0.17 | 0.26 | 0.29 | 1.9 | 2.15 | 6.23 | 6.45 | +6.28 |
| Public | 31.95 | 32.2 | 32.11 | 32.07 | 32.07 | 32.06 | 33.65 | 33.27 | +1.32 |
Mutual fund holdings · Oct 2026
0 schemes hold this stock
0 the month before.
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for Beta Drugs Ltd are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about Beta Drugs Ltd
What is the Beta Drugs Ltd share price?
Beta Drugs Ltd (BETA) last closed at ₹1,764.20, down 2.11% on the day. Its 52-week range is ₹1,030.30 to ₹2,668.30.
What is the market cap of Beta Drugs Ltd?
Beta Drugs Ltd has a market capitalisation of about ₹1,827 crore. Its price-to-earnings ratio is 37.2.
How are Beta Drugs Ltd's latest results?
Return on equity was 17.0% in Mar 2026. Promoter holding was 58.91% in Sep 2026, down 7.82 points over 8 quarters.
Who owns Beta Drugs Ltd?
As of Sep 2026, shareholding was: Promoter 58.91%, FII 1.37%, DII 6.45%, Public 33.27%.
How many mutual funds hold Beta Drugs Ltd?
0 mutual fund schemes held Beta Drugs Ltd in October 2026. That compares with 0 the month before.
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.